Earnings Call Intelligence Subscribe
Home › Call Sheets › REGN › Q3'25
Call sheet · Q3'25

Regeneron Pharmaceuticals (REGN)

Q3'25 earnings call · held October 28, 2025 · compared with the Q2'25 call · management-credibility review
10/12
Disclosure score
6 low flags
Financial quality
Bottom line
The sleeper story is Regeneron's quiet transformation into a hematology powerhouse with Lynozyfic showing unprecedented 100% response rates that could capture meaningful share of a $30B market. While everyone obsesses over EYLEA manufacturing delays, the real binding constraint is patient affordability headwinds that won't be solved by charity - the Good Days matching program's spectacular failure proves this. Len's quote says it all: 'disappointed to report that the match was under $1 million due to lack of donations.' The 18% sequential unit demand growth for EYLEA HD shows the underlying product strength remains intact once access issues resolve. My view changes if Lynozyfic Phase III data in earlier-line settings disappoints or if they can't solve the structural affordability crisis affecting the entire retina category.

The 30-second version

  • The sleeper story: REGN quietly becoming a hematology powerhouse while everyone obsesses over EYLEA delays
  • EYLEA HD manufacturing delays are noise, but the real signal is demand acceleration to 18% sequential unit growth
  • Red flag: Patient affordability crisis deepening with matching fund failing spectacularly

What changed this quarter

MetricQ2'25Q3'25Change
Total Revenue$3.7B (Q2) +4% YoY$3.8B (Q3) +1% YoYDeceleration to +1% growth
Dupixent Global Sales$4.3B (Q2) +21% YoY$4.9B (Q3) +26% YoYAccelerated +500 bps to 26%
EYLEA HD US Sales$393M (Q2) +29% YoY$431M (Q3) +10% YoYAll-time high but growth decelerated -1900 bps
EYLEA US Sales$754M (Q2) -39% YoY$681M (Q3) continuing decline10% sequential decline continues
Libtayo Global Sales$377M (Q2) +25% YoY$365M (Q3) +24% YoYStable at 24% growth
Diluted EPS$12.89 (Q2) +12% YoY$11.83 (Q3)Sequential decline of -8%
R&D Expense$1.3B (Q2)$1.3B (Q3)Flat sequentially but 2026 guided mid-teens increase
EYLEA HD Unit Demand+16% sequential (Q2)+18% sequential (Q3)Accelerated unit demand growth
Sanofi Development Balance$1.2B (Q2)$900M (Q3)Reduced $300M in quarter, $730M YTD
Free Cash Flow 9M$1.7B (6M)$3.2B (9M)Strong cash generation continues

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full REGN Q3'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.